Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Cataract extraction with IOL, with and without glaucoma stents; the ASC volume engine. Main billing specialty: ophthalmology.
Medicare fee-for-service cataract & MIGS cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 7% on average (255 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 945 | 147,381−0.7%/yr | −0.7%/yr | 43.20.8× | 82% | 160,000 in 2030+1.4%/yr |
| Texas | 638 | 117,786−2.6%/yr | −2.6%/yr | 53.61.0× | 88% | 129,100 in 2030+1.5%/yr |
| Florida | 588 | 114,602−2.3%/yr | −2.3%/yr | 50.40.9× | 95% | 126,900 in 2030+1.7%/yr |
| New York | 588 | 82,565−2.7%/yr | −2.7%/yr | 44.50.8× | 75% | 85,900 in 2030+0.7%/yr |
| Minnesota | 153 | 81,628+7.9%/yr | +7.9%/yr | 176.33.1× | 69% | 138,000 in 2030+9.1%/yr |
| North Carolina | 248 | 74,301+0.5%/yr | +0.5%/yr | 73.41.3× | 66% | 87,500 in 2030+2.8%/yr |
| Ohio | 292 | 74,196−1.5%/yr | −1.5%/yr | 65.81.2× | 76% | 79,700 in 2030+1.2%/yr |
| Virginia | 225 | 73,424+1%/yr | +1%/yr | 69.11.2× | 87% | 82,800 in 2030+2%/yr |
| Pennsylvania | 390 | 72,726−1.7%/yr | −1.7%/yr | 52.40.9× | 80% | 74,300 in 2030+0.4%/yr |
| Illinois | 317 | 67,303−0.8%/yr | −0.8%/yr | 48.00.9× | 70% | 75,800 in 2030+2%/yr |
| Tennessee | 167 | 60,859+2.6%/yr | +2.6%/yr | 85.11.5× | 93% | 72,000 in 2030+2.8%/yr |
| Massachusetts | 256 | 48,337+1.2%/yr | +1.2%/yr | 50.40.9× | 83% | 55,500 in 2030+2.3%/yr |
| Georgia | 221 | 47,191−3.3%/yr | −3.3%/yr | 53.61.0× | 89% | 50,000 in 2030+1%/yr |
| Indiana | 139 | 45,606−2.5%/yr | −2.5%/yr | 63.61.1× | 83% | 44,900 in 2030−0.3%/yr |
| South Carolina | 144 | 45,000+1.8%/yr | +1.8%/yr | 64.61.1× | 89% | 59,900 in 2030+4.9%/yr |
| New Jersey | 259 | 44,451−1.6%/yr | −1.6%/yr | 41.80.7× | 95% | 46,300 in 2030+0.7%/yr |
| Washington | 195 | 42,031−2.8%/yr | −2.8%/yr | 53.91.0× | 87% | 43,500 in 2030+0.6%/yr |
| Arizona | 159 | 41,851+0.2%/yr | +0.2%/yr | 55.51.0× | 97% | 45,100 in 2030+1.3%/yr |
| Michigan | 304 | 41,610−7.1%/yr | −7.1%/yr | 48.20.9× | 76% | 38,700 in 2030−1.2%/yr |
| Maryland | 198 | 39,250−1.2%/yr | −1.2%/yr | 44.00.8× | 91% | 41,300 in 2030+0.8%/yr |
| Wisconsin | 145 | 38,264+1.4%/yr | +1.4%/yr | 66.51.2× | 58% | 52,200 in 2030+5.3%/yr |
| Alabama | 102 | 35,688−2.7%/yr | −2.7%/yr | 79.51.4× | 83% | 29,500 in 2030−3.1%/yr |
| Missouri | 163 | 35,677−3.1%/yr | −3.1%/yr | 56.51.0× | 81% | 35,000 in 2030−0.3%/yr |
| Oklahoma | 85 | 29,510−2.8%/yr | −2.8%/yr | 60.01.1× | 81% | 28,700 in 2030−0.5%/yr |
| Kentucky | 91 | 27,713−3.2%/yr | −3.2%/yr | 59.31.1× | 80% | 29,700 in 2030+1.2%/yr |
| Colorado | 127 | 26,813−0.4%/yr | −0.4%/yr | 54.01.0× | 87% | 31,400 in 2030+2.7%/yr |
| Connecticut | 117 | 25,053−0.3%/yr | −0.3%/yr | 74.21.3× | 80% | 30,200 in 2030+3.2%/yr |
| Kansas | 67 | 23,142−1.6%/yr | −1.6%/yr | 56.61.0× | 78% | 24,400 in 2030+0.9%/yr |
| Louisiana | 120 | 22,385−5.1%/yr | −5.1%/yr | 53.71.0× | 61% | 20,400 in 2030−1.5%/yr |
| Mississippi | 74 | 21,062−3.1%/yr | −3.1%/yr | 55.31.0× | 96% | 21,400 in 2030+0.3%/yr |
| Oregon | 132 | 19,5390%/yr | 0%/yr | 45.70.8× | 85% | 23,200 in 2030+2.9%/yr |
| Arkansas | 64 | 19,041−6%/yr | −6%/yr | 49.60.9× | 87% | 22,100 in 2030+2.5%/yr |
| Iowa | 68 | 18,172−5.5%/yr | −5.5%/yr | 40.40.7× | 61% | 20,600 in 2030+2.1%/yr |
| Nebraska | 48 | 17,332+0.1%/yr | +0.1%/yr | 65.81.2× | 75% | 20,900 in 2030+3.2%/yr |
| Utah | 100 | 16,336−0.9%/yr | −0.9%/yr | 73.31.3× | 75% | 15,600 in 2030−0.8%/yr |
| Nevada | 55 | 13,217−6.7%/yr | −6.7%/yr | 45.10.8× | 98% | 14,000 in 2030+1%/yr |
| South Dakota | 28 | 11,938−0.1%/yr | −0.1%/yr | 90.91.6× | 84% | 13,900 in 2030+2.5%/yr |
| New Hampshire | 45 | 10,8700%/yr | 0%/yr | 47.30.8× | 79% | 12,900 in 2030+2.8%/yr |
| Montana | 31 | 9,758−0.6%/yr | −0.6%/yr | 50.70.9× | 83% | 10,100 in 2030+0.6%/yr |
| New Mexico | 34 | 9,620−3.6%/yr | −3.6%/yr | 41.10.7× | 92% | 10,700 in 2030+1.8%/yr |
| Idaho | 39 | 9,223+0.2%/yr | +0.2%/yr | 44.50.8× | 99% | 11,200 in 2030+3.3%/yr |
| Delaware | 21 | 8,893+2%/yr | +2%/yr | 51.30.9× | 94% | 10,900 in 2030+3.5%/yr |
| West Virginia | 40 | 8,511−8.6%/yr | −8.6%/yr | 40.00.7× | 46% | 6,820 in 2030−3.6%/yr |
| North Dakota | 23 | 8,264+1.9%/yr | +1.9%/yr | 82.01.5× | 78% | 9,110 in 2030+1.6%/yr |
| Rhode Island | 27 | 7,5280%/yr | 0%/yr | 80.91.4× | 89% | 11,900 in 2030+7.9%/yr |
| Hawaii | 42 | 5,492−2.8%/yr | −2.8%/yr | 42.10.7× | 94% | 5,990 in 2030+1.4%/yr |
| Maine | 24 | 5,023−10%/yr | −10%/yr | 31.20.6× | 86% | 4,850 in 2030−0.6%/yr |
| Vermont | 17 | 4,085−6.1%/yr | −6.1%/yr | 35.40.6× | 63% | 6,680 in 2030+8.5%/yr |
| District of Columbia | 29 | 3,191+3%/yr | +3%/yr | 50.10.9× | 95% | 4,020 in 2030+3.9%/yr |
| Alaska | 17 | 3,008−6%/yr | −6%/yr | 25.00.4× | 85% | 3,720 in 2030+3.6%/yr |
| Wyoming | 5 | 1,991−3.7%/yr | −3.7%/yr | 18.20.3× | 92% | 2,190 in 2030+1.6%/yr |
Professional codes (what the surgeon bills): CPT 66984, 66982, 66989, 66991, 66987, 66988, 65820, 66174, 66183, 0671T, 0449T.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 501 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 17 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Alcon | 167 |
| Johnson & Johnson MedTech | 117 |
| Bausch & Lomb | 57 |
| Carl Zeiss Meditec | 32 |
| Hoya Surgical Optics | 31 |
| Rayner Intraocular Lenses | 30 |
| Glaukos | 28 |
| Lenstec | 14 |
| Starr Surgical | 8 |
| Bausch And Lomb | 4 |
| New World Medical | 4 |
| Bausch+Lomb | 2 |
Product codes: HQC (unit, phacofragmentation), HQL (intraocular lens), KYF (implant, eye valve), OGO (intraocular pressure lowering implant). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +7 pts since 2019, to 83%.
The 10 busiest do 7% of the cases CMS names in California; 439 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Vitreoretinal surgery | 1,078 | 78,831−3.2%/yr | −3.2%/yr | 82,600 in 2030+0.8%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 25 companies reported engagement with surgeons in the covered states worth $17M in consulting, speaking, meals and travel tied to these products, about $2,068 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.